POLD1 and neoplasm: We discovered that DNA polymerase (POLD1) pedigree mutations might be a risk factor for BLCA and that patients with POLD1G178R mutations tended to have higher tumor mutation burden (TMB), immune cell invasion, and longer survival times than patients with POLD1 wild-type BLCA6.